Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment

Tyrosine kinase inhibitors (TKIs) such as vandetanib have shown clinical effectiveness in advanced medullary thyroid cancer (MTC). During TKI treatment, fluctuations in the tumor markers carcinoembryonic antigen (CEA) and calcitonin (CTN) are frequently observed. Their role for treatment monitoring...

Descripción completa

Detalles Bibliográficos
Autores principales: Werner, R.A., Schmid, J.S., Muegge, D.O., Lückerath, K., Higuchi, T., Hänscheid, H., Grelle, I., Reiners, C., Herrmann, K., Buck, A.K., Lapa, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912293/
https://www.ncbi.nlm.nih.gov/pubmed/26559299
http://dx.doi.org/10.1097/MD.0000000000002016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912293/
https://www.ncbi.nlm.nih.gov/pubmed/26559299
http://dx.doi.org/10.1097/MD.0000000000002016

Ejemplares similares